Information Provided By:
Fly News Breaks for April 5, 2017
IMPV
Apr 5, 2017 | 09:05 EDT
Stephens analyst Jonathan Ruykhaver remains convinced Imperva is positioned for a re-acceleration in overall growth driven by DAM and Incapsula. Overall, the analyst anticipates Q1 results ahead of consensus expectations, and believes focused execution and improved fundamentals can support revenue growth of over 20% and accelerating leverage in 2017. He reiterates an Overweight rating and $53 price target on the shares.
News For IMPV From the Last 2 Days
There are no results for your query IMPV
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.